Cancer Prostate Clinical Trial
Official title:
Prostatic Specific Membrane Antigen Reporting and Data System (PSMA-RADS) Version 1.0: Prospective Validation and Comparison to Updated Version (v2.0)
This is a prospective, multicenter study aimed at evaluating the diagnostic accuracy and reliability of the Prostate-Specific Membrane Antigen Reporting and Data System (PSMA-RADS) version 1.0 in detecting prostate cancer using 68Ga-PSMA-11 PET/CT imaging. The study also compared the performance of PSMA-RADS v1.0 with the updated version 2.0. Key points: - 186 patients with newly diagnosed or recurrent prostate cancer underwent 68Ga-PSMA-11 PET/CT imaging. - Three radiologists independently evaluated the scans and assigned PSMA-RADS scores using v1.0, then retrospectively using v2.0. - Diagnostic accuracy was assessed against histopathology and follow-up imaging as reference standards. - Inter-rater agreement was evaluated using Fleiss' kappa statistic. - The study aimed to validate the diagnostic utility of PSMA-RADS v1.0 and compare it to the updated v2.0.
Study Design and Patient Population: - This was a prospective, multicenter study conducted across three institutions from January 2023 to March 2024. - 208 consecutive patients were initially recruited, with 186 patients included in the final cohort after exclusions (52 newly diagnosed, 134 with biochemical recurrence). - Key exclusion criteria were inability to undergo PET/CT, allergy to contrast, hepatic/renal impairment, and loss to follow-up. Imaging Protocol: - All patients underwent 68Ga-PSMA-11 PET/CT imaging on integrated PET/CT scanners. - Detailed acquisition protocol is provided, including patient preparation, radiotracer dosing, low-dose CT, PET acquisition, and diagnostic contrast-enhanced CT. Image Analysis: - Three experienced nuclear medicine radiologists independently evaluated the anonymized PET/CT images in random order, blinded to clinical data. - They underwent standardized training on PSMA-RADS criteria before the study. - For each patient, the scan was divided into 4 regions: prostate/bed, lymph nodes, bones, soft tissues. - Each region was assessed for uptake intensity, sites relevant for metastases, and CT lesion definition. - Radiologists assigned PSMA-RADS categories (1-5) to each region and an overall patient score using v1.0 criteria. - Retrospectively, they re-assigned scores using the updated PSMA-RADS v2.0 criteria after its publication in July 2023. Reference Standard: - For newly diagnosed patients, the reference was histopathology from biopsies within 2 weeks before imaging. - For biochemical recurrence, the reference was histopathology from biopsies (n=151) or 1-year clinical/imaging follow-up (n=37). Statistical Analysis: - Diagnostic accuracy was evaluated using a 4-fold table against the reference standard. - ROC analysis was performed to determine optimal cut-offs and AUCs. - Inter-rater agreement was assessed using Fleiss' kappa statistic. - Performance of PSMA-RADS v1.0 and v2.0 were compared. In summary, this prospective study rigorously evaluated the diagnostic performance and reliability of PSMA-RADS v1.0 on a multi-center cohort using 68Ga-PSMA-11 PET/CT, and compared it head-to-head with the updated version 2.0, with thorough statistical analyses planned. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06152419 -
Patient Education Videos to Improve Patients' Experience During Radiotherapy Treatment: a National Project
|
N/A | |
Active, not recruiting |
NCT05410002 -
Diet Effect on Cancer Treatment Outcome
|
Phase 1 | |
Completed |
NCT04836221 -
Comorbidities And Reducing inEquitieS
|
N/A | |
Terminated |
NCT03157856 -
Assessment of a New Fluorescence Imaging Technique Using Biopsies From Prostate Resection
|
||
Not yet recruiting |
NCT06035731 -
Evaluation of the Medical Service by Socio-aesthetics in Oncology
|
N/A | |
Not yet recruiting |
NCT05154474 -
Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy
|
||
Recruiting |
NCT03452774 -
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
|
||
Completed |
NCT00172055 -
Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy
|
Phase 3 | |
Completed |
NCT04074460 -
Volatile Anaesthesia and Perioperative Outcomes Related to Cancer Feasibility Study
|
Phase 4 | |
Completed |
NCT03866785 -
Physical Activity Experiment on Male Prostate Cancer Patients
|
N/A |